Rockwell Medical amends DaVita supply agreement with price increase, one-time payment

ROCKWELL MEDICAL, INC.

DaVita agrees to increased product pricing for dialysis concentrates effective Sept 1, 2023, plus a one-time payment to Rockwell after Dec 1, 2023.
Amended agreement runs through Dec 31, 2024; DaVita can extend to Dec 31, 2025 with further price increase.
DaVita must provide 9-month purchase forecasts and commit to buy at least forecasted amounts or pay shortfall.
Upon termination, Rockwell will provide transition services to DaVita if requested.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ROCKWELL MEDICAL, INC. amended Amended and Restated Products Purchase Agreement with DaVita Inc. (effective 2023-09-18).

Action: amendment
Agreement: supply
Counterparty: DaVita Inc.
Effective: 2023-09-18

Exact text from the filing

On September 18, 2023, Rockwell Medical, Inc. (the “Company”) and DaVita Inc. (“DaVita”) entered into an Amended and Restated Products Purchase Agreement (the “Amended Agreement”), which amends and restates the Products Purchase Agreement, dated July 1, 2019, as amended, under which the Company supplies DaVita with certain dialysis concentrates.

View on SEC.gov

Browse all material agreements →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-032719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.